Clinical Trial Update: Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the RenalGuard System to reduce contrast-induced nephropathy in at-risk patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• RenalGuard System

Snippet

Sponsor: CardioRenal Systems, Inc. | Conditions: Contrast Induced Nephropathy | Phase 3 | Status: UNKNOWN